ArticleJournal of veterinary internal medicine2026
Effect of amiodarone, diltiazem, or both to achieve strict heart rate control in dogs with atrial fibrillation.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundDogs with atrial fibrillation (AF) live longer if heart rate is strictly controlled (SHRC, 24-h mean heart rate ≤ 125 beats per minute [bpm]). Amiodarone and diltiazem are used to lower ventricular response rate (VRR) in dogs with AF, but information about their relative efficacy for achieving SHRC is lacking. HYPOTHESIS/
objectivesDescribe heart rate response with sequential escalation of amiodarone or diltiazem monotherapy to combination therapy. ANIMALS: Thirteen client-owned dogs with AF.
methodsProspective cohort study with an adaptive treatment protocol. Dogs with AF with mean daily heart rate (MDHR) > 125 bpm (baseline, 24-h Holter) were randomized to receive amiodarone or diltiazem at standard doses. Dogs were reassessed 21 days later, and the other drug (amiodarone or diltiazem) was added if SHRC was not achieved. Dogs were then reassessed at 42 and 63-147 days after starting treatment. If MDHR >125 bpm at any repeat assessment, the second drug was added. Timing of final assessment was dependent on whether treatment was escalated.
resultsMonotherapy with amiodarone and diltiazem was initially used in 7 and 6 dogs, respectively. SHRC was achieved in 3 dogs (amiodarone, n = 2; diltiazem, n = 1) at first follow-up. At last follow-up, 11 of 13 dogs were receiving both drugs (median [range] 50 [20-153] days). Combination therapy of amiodarone and diltiazem did not result in SHRC (139 [94-160] bpm) in most dogs (7/11, 64%). CONCLUSIONS AND CLINICAL IMPORTANCE: Monotherapy with amiodarone or diltiazem or combination therapy of amiodarone/diltiazem did not achieve SHRC in most dogs in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.